{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-25-000069","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.065669+00:00","generated_at":"2026-05-17T22:25:27.346852+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nautilus Q2 net loss narrows to $15.0M; cash $179.5M; platform milestone","bullets":["Operating expenses $17.1M, down 18% YoY from $20.8M.","Net loss $15.0M improved from $18.0M loss in Q2 2024.","Cash, equivalents and investments $179.5M as of June 30, 2025.","Published first scientific manuscript validating Iterative Mapping method for proteoform measurement.","Signed two collaborations to study Tau proteoforms in Alzheimer's disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-25-000069","json":"https://secwatch.observer/filing/0001808805-25-000069.json","markdown":"https://secwatch.observer/filing/0001808805-25-000069.md","text":"https://secwatch.observer/filing/0001808805-25-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000069/0001808805-25-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000069/naut-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:25:27.346852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}